Edition:
United States

Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

139.64USD
24 Mar 2017
Change (% chg)

$0.67 (+0.48%)
Prev Close
$138.97
Open
$138.97
Day's High
$140.50
Day's Low
$138.04
Volume
499,178
Avg. Vol
769,634
52-wk High
$153.14
52-wk Low
$67.54

Latest Key Developments (Source: Significant Developments)

Incyte to replace Spectra Energy in S&P 500
Thursday, 23 Feb 2017 05:57pm EST 

: S&P Dow Jones Indices - Incyte will replace Spectra Energy in the S&P 500 effective at the open of trading on February 28 .S&P Dow Jones Indices - CBOE Holdings will replace Pitney Bowes in the S&P 500.  Full Article

Incyte Corp says entered into letter agreement with certain entities affiliated with Julian Baker - SEC filing
Tuesday, 21 Feb 2017 08:37am EST 

Incyte Corp : Incyte Corp- entered into a letter agreement, dated February 17, 2017 with certain entities affiliated with Julian Baker - SEC filing . Incyte Corp - pursuant to agreement, baker entities agreed to exchange $259 million co's 0.375 pct notes due 2018,$274.5 million co's 1.25 pct notes due 2020 .Incyte Corp - agreement in exchange for an aggregate of 10.6 million shares of company's common stock, $.001 par value per share - SEC filing.  Full Article

Incyte reports Q4 earnings per share $0.05
Tuesday, 14 Feb 2017 07:00am EST 

Incyte Corp : Incyte reports 2016 fourth-quarter and year-end financial results, provides 2017 financial guidance and updates on key clinical programs . Q4 revenue $326 million versus I/B/E/S view $324.4 million . Q4 earnings per share $0.05 . Q4 earnings per share view $0.13 -- Thomson Reuters I/B/E/S . Sees 2017 Jakafi net product revenues $1,020-$1,070 million . Sees 2017 ongoing research and development expenses $785-$835 million . Sees 2017 change in fair value of acquisition-related contingent consideration $30-$35 million . Incyte Corp - pivotal program of ruxolitinib as a treatment for patients with essential thrombocythemia is also expected to begin in 2017 .Incyte - phase 3 trials in steroid-refractory acute, steroid-refractory chronic gvhd, respectively, expected to begin in 2017 with novartis.  Full Article

Immunovaccine says Princess Margaret Cancer Centre to conduct Phase 2 clinical trial to evaluate use of co, Merck's combination of immunotherapies
Monday, 6 Feb 2017 07:05am EST 

Immunovaccine Inc : Immunovaccine's lead immuno-oncology candidate to enter investigator-sponsored Phase 2 clinical trial in ovarian cancer in combination with approved anti-PD-1 drug . Princess Margaret Cancer Centre to conduct Phase 2 clinical trial to evaluate use of combination of immunotherapies from co and Merck . Expects to announce top-line interim results for Phase 1B trial of DPX-Survivac by end of March 2017 .In addition to Phase 2 trial, Immunovaccine is conducting a phase 1B trial with Incyte Corporation.  Full Article

U.S. FDA extends review period for Baricitinib, an investigational rheumatoid arthritis treatment
Friday, 13 Jan 2017 04:51pm EST 

Incyte Corp : U.S. FDA extends review period for baricitinib, an investigational rheumatoid arthritis treatment . Incyte Corp says delay does not affect Lilly's previously-issued financial guidance for 2017 . Incyte - FDA extended action date to allow time to review additional data analyses recently submitted by Lilly in response to FDA's information requests .Incyte- Submission of additional information was determined by FDA to constitute major amendment to NDA, resulting in extension of PDUFA date by 3 months.  Full Article

Incyte and Merus announce global strategic research collaboration
Wednesday, 21 Dec 2016 07:00am EST 

Incyte Corp : Incyte and Merus announce global strategic research collaboration to discover and develop bispecific antibodies . Incyte to make up-front payment of $120 million and purchase $80 million of Merus common shares . Merus eligible to receive potential development, regulatory and commercial milestones and sales royalties . Parties have agreed to collaborate on development and commercialization of up to 11 bispecific antibody programs . Merus will retain all rights to develop and commercialize approved products in united states . Merus also has option to co-fund development of product candidates arising from two other programs . Incyte - for eight programs merus to be eligible to get potential development, regulatory and sales milestone payments of up to $350 million per program . Incyte will develop and commercialize approved products arising from program outside united states . For eight programs Incyte has agreed to independently fund all development and commercialization activities .Merus also eligible to receive tiered royalties ranging from 6 to 10 percent on global sales of approved products under 8 programs.  Full Article

Incyte reported Q2 EPS $0.18
Tuesday, 9 Aug 2016 07:00am EDT 

Incyte Corp : Quarter financial results and updates key clinical programs . Q2 earnings per share $0.18 . Q2 earnings per share view $-0.02 -- Thomson Reuters I/B/E/S . Q2 revenue $246 million versus I/B/E/S view $234.5 million .Sees 2016 Jakafi net product revenue $825 mln - $835 million.  Full Article

Agenus Inc starts phase 1/2 clinical trial of anti-GITR agonist antibody
Wednesday, 22 Jun 2016 08:50am EDT 

Agenus Inc : Expect to initiate additional clinical studies with antibodies and immuno-oncology leads from comprehensive pipeline in next twelve months .Agenus announces commencement of phase 1/2 clinical trial of anti-GITR checkpoint antibody INCAGN1876 in patients with solid tumors.  Full Article

Incyte announces phase 3 data of Jakafi study
Friday, 10 Jun 2016 02:35am EDT 

Incyte Corp : Says announced new 28-week data from phase 3 response-2 study of Jakafi . Says data show that Jakafi was superior to best available therapy in maintaining hematocrit control . Says safety profile of Jakafi was consistent with previous studies . Study shows that nearly five times more patients with pv achieved complete hematologic remission with Jakafi compared to bat at 28 weeks . Says overall, Jakafi was well tolerated . Says findings from this study are consistent with data from response pivotal trial .New phase 3 data show Jakafi (ruxolitinib) is superior to best available therapy in patients with polycythemia vera.  Full Article

Immunovaccine says net loss, comprehensive loss of $1.85 mln for Q1
Tuesday, 10 May 2016 05:40pm EDT 

Immunovaccine Inc : Says net loss and comprehensive loss of $1,852,000 for Q1 fiscal 2016 .Immunovaccine announces financial results for quarter ended March 31, 2016.  Full Article

More From Around the Web

BRIEF-Incyte to replace Spectra Energy in S&P 500

* S&P Dow Jones Indices - Incyte will replace Spectra Energy in the S&P 500 effective at the open of trading on February 28